Identification of a new serum biomarker for clinically significant prostate cancer

December 8, 2020

Exciting new results from our lab collaborative work reveal PTN as a new serum biomarker of pro-metastatic prostate cancer. Congratulations Shiqin and all collaborators!

https://www.nature.com/articles/s41416-020-01200-0

December 8, 2020

PreviousIdentification of a new important regulator of prostate cancer growth and metastasis
NextDiscovery of ferroptosis inducers as a new therapeutic strategy for advanced prostate cancer

Related Posts ...

Exciting news: Dr. Hyeonji Hwang, a postdoctoral fellow at Dr. Stoyanova’s Lab in UCLA, awarded the Prostate Cancer Research Program Early Investigator Research Award by the US Department of Defense (DOD) for the project titled “Targeting Trop2-Mediated Ferroptosis as a New Therapy for Advanced Prostate Cancer”

Exciting News: Dr. Tanya Stoyanova receives 2025 Neuroendocrine Tumor Research Foundation Pilot Award